1. FDA OKs an eighth use for JNJ’s Xarelto — Roche’s Rituxan shows superiority in autoimmune skin condition — Sun Pharma launches dry eye disease treatment in US — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

JP-Morgan Gossip: Buying ACORDA

Discussion in 'Acadia Pharmaceuticals' started by anonymous, Jan 13, 2019 at 9:13 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Is it true ?
    A buddy who is part of the JP-Morgan crowd told me that Acadia is seriously looking at buying Acorda and their inhaled levodopa.
     
  2. anonymous

    anonymous Guest

    It will be an excellent fit the for us - great move by our BD people.
     
  3. anonymous

    anonymous Guest

    It’s about bloody time. We need to expand our portfolio even if it is a me too product. Let’s build this company!
     
  4. anonymous

    anonymous Guest

    This is BS. We barely have $400 million dollars. We have to spend that money on our commercial expansions and ongoing clinical trials.
     
  5. anonymous

    anonymous Guest

    No, it isn't
    There are ways that Bankers can pull this M&A together.
    Plus SO MUCH SYNERGY of call-points.

    Pity if our BD folks are not thinking about this one.
     
  6. anonymous

    anonymous Guest

    One of my prescribing docs is very excited about Inbrija.
    He thinks it is going to be a super-winner.

    It be awesome if we get another product soon.
    I can see the great logic on buying Acorda
     
  7. anonymous

    anonymous Guest

    Let’s be real, this acquisition will have us selling a me too... just a different delivery. We know that we can’t rely on pipelines, so unless rHIgM22 breaks through strap in for an uneventful product.
     
  8. anonymous

    anonymous Guest

    Is not a me-too at all
    You know very little of the rescue of on-off
    READ and EDUCATE yourself before you speak
     
  9. anonymous

    anonymous Guest

    Let's buy Acorda
    We need more products or we die as a company
     
  10. anonymous

    anonymous Guest

    It’s inhaled LD dipshit. Nothing new or novel about it except the price tag.
     
  11. anonymous

    anonymous Guest

    Clear that you don't know PD and the on-off unmet medical need.

    This will be a great product for us as a P2
     
  12. anonymous

    anonymous Guest

    Acadia is currently in a 3 month negotiation period with neuren pharmaceuticals for the rest of the world rights for trofinetide. Makes more sense they would buy out neuren.
     
  13. anonymous

    anonymous Guest

     
  14. anonymous

    anonymous Guest

    Who ever said that doesn't know this business AT ALL! Every drug thats ever sold has a delivery system. THAT is a crucial part of development. The success of a product often times depends solely on its delivery system, even if its an older drug, a novel delivery system makes it new again. inbrija will be wildly successful IF the sales team is worth a salt.